INTERVIEW: $HPQ.ca Discusses $ 5.25M Financing + PUREVAP™ Process Update
Thousands of worldwide #gamers flock to Vancouver for massive #Esports tournament $GMBL #Overwatch #DOTA #FORTNITE
Zebi Launches a #Blockchain Solution for #Education in #India $BTRU.ca
CLIENT FEATURE: American Creek $AMK.ca encounters high grade #Gold / #Silver at Treaty Creek, same system as #Seabridge Gold $SX $SEA.ca $SKE.ca $TUD.ca $PVG $MRO.ca
betterU Education Corporation $BTRU.ca Adds New Education Partners to Platform Now Totalling More Than 20,000 Courses $ARCL $CPLA $BPI $FC.ca
$GGX.ca GGX Gold Drilling Intersects 50.1 g/t Gold and 375 g/t Silver over 2.05 Meters — Gold Drop Property, Southern British Columbia GGX Gold $K.ca

- Results for 2018 holes COD18-43 to COD18-45 which tested the COD Vein, in the Gold Drop Southwest Zone.
- COD18-45 returned 50.1 grams per tonne (g/t) gold and 375 g/t silver over 2.05
- 2018 drilling program also tested the continuation of the Everest Vein, which is located approximately 600 meters southwest of the COD Vein worksite.
GGX Gold Corp. (TSX-v: GGX), (OTCQB: GGXXF), (FRA: 3SR2) (the “Company†or “GGXâ€) is pleased to announce it has received additional analytical results from its diamond drilling program on the Gold Drop property, located near Greenwood, B.C. Drill core analytical results have been received for 2018 drill holes COD18-43 to COD18-45 which tested the COD Vein. The COD gold bearing vein is located in the Gold Drop Southwest Zone.

Gold bearing quartz vein with high grade gold in drill hole COD18-45
(50.1 g/t gold over 2.05meters)
To view the graphic in its original size, please click here
The highlight from these analytical results is an intersection of 50.1 grams per tonne (g/t) gold and 375 g/t silver over 2.05 meter core length in drill hole COD18-45 which tested the COD Vein, including 167.5 g/t gold, 1,370 g/t silver and >500 g/t tellurium over 0.46 meter core length. This gold-bearing intersection of quartz veins and altered granodiorite in COD18-45 is located at approximately 20 meter vertical depth and approximately 160 meters southwest of the area of 2017 trenching at the COD Vein. COD18-45 is located approximately 220 meters southwest of drill hole COD17-14 which intersected the 4.59 g/t gold over 16.03 meters, including 10.96 g/t gold over 5.97 meters (News Release of September 7, 2017).
The 2018 drilling program focused on testing and defining the COD Vein, a Dentonia/Jewel style quartz vein. Trenching during 2017 exposed the northeast – southwest striking COD Vein for over 160 meter strike length. The 2018 drilling program also tested the continuation of the Everest Vein, which is located approximately 600 meters southwest of the COD Vein worksite. The Everest Vein was first discovered by Company prospectors during the 2017. Chip samples collected in 2017 across the approximate 0.4 meter wide vein exposure returned up to 52.8 g/t gold and 377 g/t silver while a grab sample of a quartz vein boulder broken off the outcrop by the excavator returned 81.8 g/t gold and 630 g/t silver (News Release of August 21, 2017).
The analytical results listed below are highlights from drill holes COD18-43 to COD18-45 (intersections greater than 1 g/t gold), testing the continuation of the COD Vein south-southwest of the 2017 trench. Since true widths cannot be accurately determined from the information available the core lengths (meters) are reported. The gold, silver and tellurium analyses are reported in grams per tonne (g/t).
Previous drill core analytical results from the 2018 drilling program are reported in News Releases of May 29, June 14, June 27, July 11, July 19, July 25, August 1 and August 9. The 2.05 meter core length intersection in drill hole COD18-45 at the COD Vein is the highlight of the 2018 drilling program to date and represents a significant intersection with high grade gold southwest of the 2017 trench. Prior to the receipt of these analytical results, the highlight of the 2018 drilling program was 14.62 g/t gold, 150.2 g/t silver and 102.0 g/t tellurium over 2.1 meter core length in drill hole COD18-3 at the COD Vein, located in the area of the 2017 trench and vicinity of drill hole COD17-14. The following map of the COD Vein work area includes some of the more significant 2017 – 2018 drill intersections.

To view the graphic in its original size, please click here
Drill core from the 2018 program was geologically logged and sampled. Drill core was sawn in half with half core samples submitted for analysis and remaining half core stored in a secure location. Core samples were delivered to the ALS Minerals laboratory in Vancouver to be analyzed for gold by Fire Assay – AA. Samples exceeding 100 g/t gold were re-analyzed for gold by Fire Assay – Gravimetric Finish. The samples were also analyzed for 48 Elements by Four Acid ICP-MS. Samples exceeding 100 g/t silver were re-analyzed for silver by Four Acid ICP-AES. Quality control (QC) samples were inserted at regular intervals.
David Martin, P.Geo., a Qualified Person as defined by NI 43-101, is responsible for the technical information contained in this News Release.
To view the Original News release with pictures please go to the website or contact the company.
On Behalf of the Board of Directors,
Barry Brown, Director
604-488-3900
PyroGenesis $PYR.ca Announces Powder Performance Results with Leading 3D Printer OEM; Now Moves into Commercial Discussions $LMT $RTN $NOC $UTX $HPQ.ca $DDD.ca $SSYS $PRLB
Genacol Canada Corporation and Tetra Bio-Pharma $TBP.ca Team Up to bring Innovative Cannabinoid Treatments to Self-Care Market in Canada $AERO $CBDS $CGRW $APH.ca $GBLX
- Announced that they have concluded a Development and Commercialization agreement with Genacol Canada Corporation.
- Tetra Bio-Pharma will develop a cannabinoid derived oral capsule and a topical cream for treating joint pain and inflammation.
ORLEANS, Ontario, Aug. 14, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that they have concluded a Development and Commercialization agreement with Genacol Canada Corporation. Tetra Bio-Pharma will develop a cannabinoid derived oral capsule and a topical cream for treating joint pain and inflammation. Genacol will be responsible for the promotion and sales of these products throughout their network in Canada. According to industry statistics the market for topical pain relief products exceeded $2.5 billion. The companies plan to launch the products in 2019.
|
Tetra Bio-Pharma will use its formulation and regulatory expertise and clinical trial data from its topical cannabinoid and encapsulated cannabis oil (PPP005) trials to create innovative products for Genacol. Tetra Bio-Pharma will work with regulatory to bring these products to markets within Genacol’s sales network.  “We are thrilled to partner with Genacol, a market leader in Canada with a sales network in over 40 countries, these products will command a great deal of exposure,†says Dr. Guy Chamberland, interim CEO and Chief Scientific Officer of Tetra Bio-Pharma. “Tetra is in the business of developing cannabinoid derived prescription and natural health products and this agreement will enable Tetra Bio-Pharma to expand the number of offerings to our patients.â€
“We are extremely excited about the potential of this partnership we have created with Tetra Bio-Pharma, a world leader in developing cannabinoid derived prescription and natural health products,†stated Martin Vidal, President & Chief Executive Office for Genacol Corporation. “Our research team at Genacol are great believers in the therapeutic properties of cannabinoids. These products that Tetra Bio-Pharma is developing and Genacol will promote and commercialize are expected to play an important role in the pain and inflammation market in Canada. We estimate that these products will generate several millions of dollars in sales for Genacol in Canada.â€
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
About Genacol Corporation
Genacol Corporation Canada is a leader in the development and marketing of natural health products primarily related to the treatment of joint pain and the maintenance of joint health. Its mission is to improve the quality of life of its customers by offering them a range of innovative natural products. Building on its success in Canada, Genacol has also developed in recent years an international presence with Genacol brand products available in more than 40 countries, including Latin America, Europe, Asia, the Middle East, Africa and the United States. In addition, the Genacol trademark is registered in 81 countries worldwide. The success of Genacol is based on its collagen manufactured using a proprietary process called “AminoLock® Sequential Technology”, which is an ingredient in many of Genacol’s products.
For more information visit: www.genacol.ca/en/about-us/
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
[email protected]
Media Contact:
ACJ Communication
Daniel Granger
[email protected]
514-840-7990
514-232-1556
Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/b867bc64-b347-4043-80ff-c7d022ab7eff
http://www.globenewswire.com/NewsRoom/AttachmentNg/3464aadf-745d-4d04-b230-b71f0c82188a

Technical crew for The International Dota 2 Championship set up the show at Rogers Arena in Vancouver,




